Exact Sciences Corporation Exact Sciences Corporation

Exact Sciences Corporation

EXAS

Rang în acțiuni #1153
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Preț acțiune
$104.91
Ultima sincronizare: 2026-03-23
Capitalizare de piață
$20.03B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
67.24%
Țară
US
Tranzacționează Exact Sciences Corporation (EXAS)

Categorie

Healthcare
Câștiguri pentru Exact Sciences Corporation (EXAS)
Câștiguri în Dec 2025 TTM: $-203.89M
Conform celor mai recente rapoarte financiare ale Exact Sciences Corporation, câștigurile actuale ale companiei sunt $-203.89M. În anul 2024, compania a înregistrat un câștig de $-1.04B, o scădere comparativ cu câștigului din 2023, care a fost de $-201.75M. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Exact Sciences Corporation din 2000 până în 2026
Câștiguri la sfârșitul fiecărui an
An Câștiguri Schimbă
2026 (TTM) $-203.89M -3.83%
2025 $-212.01M -79.54%
2024 $-1.04B 413.60%
2023 $-201.75M -68.11%
2022 $-632.57M -24.92%
2021 $-842.51M 1.62%
2020 $-829.06M 103.98%
2019 $-406.44M 132.18%
2018 $-175.06M 52.78%
2017 $-114.58M -31.47%
2016 $-167.21M 5.96%
2015 $-157.80M 57.73%
2014 $-100.05M 115.09%
2013 $-46.51M -11.27%
2012 $-52.42M 82.81%
2011 $-28.68M 148.14%
2010 $-11.56M 26.60%
2009 $-9.13M -6.29%
2008 $-9.74M -18.55%
2007 $-11.96M -7.40%
2006 $-12.92M -11.05%
2005 $-14.52M -21.61%
2004 $-18.52M -34.64%
2003 $-28.34M -5.16%
2002 $-29.88M -99.87%
2001 $-23.49B 176,087.09%
2000 $-13.33M 0.00%
Câștiguri pentru companii similare sau concurente
Companie Câștiguri Diferență de câștiguri Țara
$7.61B -3,831.95%
US
$4.76B -2,435.60%
US
$-252.70M 23.94%
US
- -
CN
$1.66B -913.19%
US